Neuro-oncology最新文献_第2页

Gene expression signature-defined necroinflammation is not associated with sex-biased survival or bevacizumab benefit in glioblastoma. 基因表达特征定义的坏死性炎症与胶质母细胞瘤的性别存活率或贝伐单抗获益无关。

IF 16.4 1区医学

Neuro-oncology Pub Date : 2024-11-15 DOI: 10.1093/neuonc/noae216

Johannes Weller, Emre Kocakavuk, Barbara Pregler, Thomas Zeyen, Niklas Schäfer, Anna-Laura Potthoff, Matthias Schneider, Ulrich Herrlinger

引用次数: 0

Sex differences show responders to bevacizumab. 性别差异显示贝伐珠单抗的应答者。

IF 16.4 1区医学

Neuro-oncology Pub Date : 2024-11-15 DOI: 10.1093/neuonc/noae217

Berta Segura-Collar, Sara Hiller-Vallina, Ricardo Gargini

引用次数: 0

Theranostics and molecular imaging in Neuro-Oncology: the beginning of a new era. 神经肿瘤学中的 Theranostics 和分子成像：新时代的开端。

IF 16.4 1区医学

Neuro-oncology Pub Date : 2024-11-15 DOI: 10.1093/neuonc/noae191

Nathalie L Albert, Matthias Preusser

引用次数: 0

Meningiomas: Sex-Specific Differences and Prognostic Implications of a Chromosome X Loss. 脑膜瘤：X 染色体缺失的性别差异和预后影响。

IF 16.4 1区医学

Neuro-oncology Pub Date : 2024-11-13 DOI: 10.1093/neuonc/noae239

Natalie Berghaus, Thomas Hielscher, Dilan Savran, Daniel Schrimpf, Sybren L N Maas, Matthias Preusser, Michael Weller, Till Acker, Christel Herold-Mende, Wolfgang Wick, Andreas von Deimling, Felix Sahm

{"title":"Meningiomas: Sex-Specific Differences and Prognostic Implications of a Chromosome X Loss.","authors":"Natalie Berghaus, Thomas Hielscher, Dilan Savran, Daniel Schrimpf, Sybren L N Maas, Matthias Preusser, Michael Weller, Till Acker, Christel Herold-Mende, Wolfgang Wick, Andreas von Deimling, Felix Sahm","doi":"10.1093/neuonc/noae239","DOIUrl":"https://doi.org/10.1093/neuonc/noae239","url":null,"abstract":"Background: Meningiomas are the most common primary intracranial tumours in adults. Several studies proposed new stratification systems with a more accurate risk prediction than the WHO grading, e.g. based on methylation and copy number variations (CNVs). Yet, common shortcomings in these analyses are either a lack of stratification by sex of patients or excluding the gonososmes from CNV assessment.Methods: Within this study, DNA methylation array data from 7,424 meningioma samples as well as targeted sequencing, clinical annotations and morphology subtyping of 796 samples were examined for differences between females and males regarding mutations, methylation classes, copy number variations and histology.Results: Meningiomas from females accounted for about 53 % of the malignant tumours and present a loss of one X chromosome in 57 % of these malignant cases. In the group of benign tumours, females comprised about 75 % of the patients. Therein, a loss of one X chromosome was detected in only about 10 % of the cases but was associated with a significantly worse progression free survival.Conclusion: Although genomic instability is a common feature of malignant meningiomas, particularly loss of the X chromosome in tumours of female patients in otherwise histologically and molecularly low-risk tumours confers higher risk. Hence, the gonosomal copy number status can be leveraged for increased diagnostic accuracy.","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":""},"PeriodicalIF":16.4,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142625036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunotherapy-Related Neurotoxicity in the Central Nervous System of Children with Cancer. 癌症儿童中枢神经系统与免疫疗法相关的神经毒性

IF 16.4 1区医学

Neuro-oncology Pub Date : 2024-11-13 DOI: 10.1093/neuonc/noae243

Jiasen He, Jeremy Connors, Andrew Meador, Shuo Xu, Heather Meador, Hong Jiang, Juan Fueyo, Candelaria Gomez-Manzano, Gregory K Friedman, Wafik Zaky, Zsila Sadighi, John M Slopis, Ali H Ahmad

{"title":"Immunotherapy-Related Neurotoxicity in the Central Nervous System of Children with Cancer.","authors":"Jiasen He, Jeremy Connors, Andrew Meador, Shuo Xu, Heather Meador, Hong Jiang, Juan Fueyo, Candelaria Gomez-Manzano, Gregory K Friedman, Wafik Zaky, Zsila Sadighi, John M Slopis, Ali H Ahmad","doi":"10.1093/neuonc/noae243","DOIUrl":"https://doi.org/10.1093/neuonc/noae243","url":null,"abstract":"Significant gaps remain in our understanding of immunotherapy-related neurotoxicity in pediatric patients, largely because much of our knowledge comes from studies in adults. Accurately identifying the adverse effects of immunotherapy in children is also challenging, owing to variations in terminology and grading systems. Moreover, the manifestation of immunotherapy-related neurotoxicity differs greatly across different diseases, various modalities, dosages, and delivery methods. Combining immunotherapy with other treatments might improve outcomes but introduces new complexities and potential for increased toxicities. Additionally, pediatric patients with intracranial malignancy have unique responses to immunotherapies and distinct neurotoxicity compared to those with extracranial malignancy. Consequently, we must enhance our understanding of the pathophysiology, prevalence, severity, and management of immunotherapy's neurotoxic effects in this vulnerable group. This review consolidates the current knowledge of immunotherapy-related neurotoxicity in pediatric oncology, highlighting various types of neurotoxicity including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and tumor inflammation-associated neurotoxicity (TIAN), among others. Furthermore, we examine the unique features of neurotoxicity associated with adoptive cellular therapy (ACT), antibody-based therapies, immune checkpoint inhibitors (ICIs), oncolytic viruses (OV), and cancer vaccines.","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":""},"PeriodicalIF":16.4,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142625032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Using a Pre-Radiation Window to Identify Potentially Active Cytotoxic Agents in Adults with Newly Diagnosed Glioblastoma. 利用放疗前窗口识别新诊断胶质母细胞瘤成人患者中潜在的活性细胞毒性药物

IF 16.4 1区医学

Neuro-oncology Pub Date : 2024-11-13 DOI: 10.1093/neuonc/noae240

Danielle A Bazer, Antonio C Wolff, Stuart A Grossman

{"title":"Using a Pre-Radiation Window to Identify Potentially Active Cytotoxic Agents in Adults with Newly Diagnosed Glioblastoma.","authors":"Danielle A Bazer, Antonio C Wolff, Stuart A Grossman","doi":"10.1093/neuonc/noae240","DOIUrl":"https://doi.org/10.1093/neuonc/noae240","url":null,"abstract":"Background: Therapies shown to improve outcomes in patients with recurrent cancers are commonly used in the neoadjuvant setting to optimize surgery, reduce radiation fields, and treat micro-metastatic disease. While pre-radiation chemotherapy (PRC) use has flourished in systemic cancers, it has not in glioblastomas. This review documents these trajectories and highlights the potential of PRC to rapidly and safely screen cytotoxic drugs for efficacy in patients with newly diagnosed glioblastoma.Methods: Prospective trials of adults with newly diagnosed systemic and brain cancers treated with PRC published between 1980 and 2023 were identified in PubMed. NCCN guidelines were used to document the standard use of PRC in patients with systemic and brain cancers.Results: Over 5,000 prospective PRC trials in solid tumors were identified. These accrued >1 million patients and resulted in neoadjuvant therapies being standard-of-care in ~28 systemic cancers. Only 50 similar trials (2,206 patients) were identified in high grade gliomas. In 13 trials containing PRC temozolomide (n=846), radiographic responses ranged from 6-53% with a median survival of ~13 months. Glioblastoma PRC trials were not associated with unexpected toxicities or major negative impacts on survival.Conclusions: PRC in patients with glioblastoma appears safe and feasible. The pre-radiation window is ideally suited to rapidly screen cytotoxic agents for efficacy. It permits radiographic response as a primary outcome, small sample sizes, and initiation of standard therapies a few months after diagnosis. PRC may be most appropriate in patients with glioblastoma who are unlikely to benefit from temozolomide.","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":""},"PeriodicalIF":16.4,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142625060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TRIM21-mediated ubiquitination and phosphorylation of ERK1/2 promotes cell proliferation and drug resistance in pituitary adenomas. TRIM21 介导的泛素化和 ERK1/2 磷酸化促进了垂体腺瘤的细胞增殖和抗药性。

IF 16.4 1区医学

Neuro-oncology Pub Date : 2024-11-13 DOI: 10.1093/neuonc/noae241

Yanting Liu, Fang Liu, Chuanbao Li, Tao Zhang, Tianyi Han, Yuting Dai, Ning Huang, Hao Tang, Xiaobin Wang, Shaojian Lin, Li Xue, Zhe Bao Wu

{"title":"TRIM21-mediated ubiquitination and phosphorylation of ERK1/2 promotes cell proliferation and drug resistance in pituitary adenomas.","authors":"Yanting Liu, Fang Liu, Chuanbao Li, Tao Zhang, Tianyi Han, Yuting Dai, Ning Huang, Hao Tang, Xiaobin Wang, Shaojian Lin, Li Xue, Zhe Bao Wu","doi":"10.1093/neuonc/noae241","DOIUrl":"https://doi.org/10.1093/neuonc/noae241","url":null,"abstract":"Background: Pituitary adenomas (PAs) are common intracranial tumors and TRIM family plays a crucial role in cell proliferation, and therapeutic resistance of tumors. However, the role of the TRIM family in PAs is not well recognized.Methods: CRISPR screening explored the role of TRIM family in the cell proliferation and drug resistance in PAs. In vitro and in vivo experiments were performed to evaluate the effects of Tripartite Motif Containing 21 (TRIM21). RNA-sequencing, mass spectrometry, immunoprecipitation and ubiquitination experiments were performed to explore the molecular mechanism. NanoBiT assays were used to screen the drugs reducing TRIM21 expression.Results: CRISPR-Cas9 screens identified that TRIM21 facilitated cell proliferation and drug resistance in PAs. Mechanistically, TRIM21 interacted with ERK1/2 through PRY-SPRY domain, leading to ERK1/2 K27-linked ubiquitination. The ERK1/2 ubiquitination promotes the interaction between ERK1/2 and MEK1/2, thereby facilitating the phosphorylation of ERK1/2. However, an excess presence of TRIM21 supressed the phosphorylation of ERK1/2 and cell proliferation via activating ERK1/2 negative feedback pathways. Importantly, TRIM21 was upregulated in dopamine-resistant prolactinomas and cabergoline-resistant MMQ cells. Furthermore, drug screening identified that Fimepinostat and Quisinostat, can reduce the protein levels of TRIM21, inhibit tumor progression, and increase drug sensitivity.Conclusions: TRIM21 may represent a therapeutic target for tumors, and inhibiting TRIM21 could be a potential strategy for tumor treatment.","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":""},"PeriodicalIF":16.4,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142625054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The prognostic impact of CDKN2A/B hemizygous deletions in IDH-mutant glioma. IDH 突变胶质瘤中 CDKN2A/B 基因半杂合子缺失对预后的影响。

IF 16.4 1区医学

Neuro-oncology Pub Date : 2024-11-12 DOI: 10.1093/neuonc/noae238

Franziska M Ippen, Thomas Hielscher, Dennis Friedel, Kirsten Göbel, David Reuss, Christel Herold-Mende, Sandro Krieg, Andreas V Deimling, Wolfgang Wick, Felix Sahm, Abigail K Suwala

{"title":"The prognostic impact of CDKN2A/B hemizygous deletions in IDH-mutant glioma.","authors":"Franziska M Ippen, Thomas Hielscher, Dennis Friedel, Kirsten Göbel, David Reuss, Christel Herold-Mende, Sandro Krieg, Andreas V Deimling, Wolfgang Wick, Felix Sahm, Abigail K Suwala","doi":"10.1093/neuonc/noae238","DOIUrl":"https://doi.org/10.1093/neuonc/noae238","url":null,"abstract":"Background: Homozygous deletions of CDKN2A/B are known to predict poor prognosis in gliomas, but the impact of hemizygous deletions is less clear. This study aimed to evaluate the prognostic significance of hemizygous CDKN2A/B deletions in IDH-mutant low-grade astrocytomas and oligodendrogliomas.Methods: Tissue samples diagnosed as astrocytoma, IDH-mutant and oligodendroglioma, IDH-mutant, 1p/19q co-deleted CNS WHO grade 2 and 3 were collected from the archives of the Institute of Neuropathology in Heidelberg. DNA methylation analysis was performed on formalin-fixed paraffin-embedded (FFPE) samples. Evaluation of the CDKN2A/B locus was performed by visual inspection of copy-number plots derived from methylation-array data for each case. Hemizygous and homozygous losses were assessed in relation to whole chromosomal or larger segmental losses and gains in the chromosomal profile. Survival probabilities were assessed using the Kaplan-Meier method.Results: A total of 334 low-grade glioma cases were identified, including 173 astrocytomas and 161 oligodendrogliomas. Hemizygous deletions in CDKN2A/B (37/173 in astrocytomas, 15/161 in oligodendrogliomas) did not confer significantly worse survival outcomes compared to CDKN2A/B wildtype cases in neither low grade astrocytoma (log-rank p= 0.2556; HR 2.29, 95% CI [0.76; 6.40], p= 0.135) nor oligodendroglioma (log-rank p= 0.2760; HR 0.17; 95% CI [0.01; 5.05]; p= 0.305), regardless of CNS WHO grade, which was further demonstrated on a subgroup of astrocytoma, IDH mutant CNS WHO 4 cases (log-rank p= 0.1680; HR 4.55, 95% CI [0.88; 24.51], p= 0.0689).Conclusions: Hemizygous CDKN2A/B deletions do not significantly worsen OS or PFS in IDH-mutant astrocytomas and oligodendrogliomas, CNS WHO grade 2 and 3.","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":""},"PeriodicalIF":16.4,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142624962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Point/Counterpoint: The role of reirradiation in recurrent glioblastoma. 观点/反观点：再照射在复发性胶质母细胞瘤中的作用。

IF 16.4 1区医学

Neuro-oncology Pub Date : 2024-11-11 DOI: 10.1093/neuonc/noae209

Rifaquat Rahman, Matthias Preusser, Christina Tsien, Emilie Le Rhun, Erik P Sulman, Patrick Y Wen, Giuseppe Minniti, Michael Weller

引用次数: 0

Glioma-Astrocyte connexin43 confers temozolomide resistance through activation of the E2F1/ERCC1 axis. 胶质瘤-星形胶质细胞Connexin43通过激活E2F1/ERCC1轴赋予替莫唑胺抗药性

IF 16.4 1区医学

Neuro-oncology Pub Date : 2024-11-08 DOI: 10.1093/neuonc/noae237

Yanping Gui, Hongkun Qin, Xinyu Zhang, Qianqian Chen, Fangyu Ye, Geng Tian, Shihe Yang, Yuting Ye, Di Pan, Jieying Zhou, Xiangshan Fan, Yajing Wang, Li Zhao

{"title":"Glioma-Astrocyte connexin43 confers temozolomide resistance through activation of the E2F1/ERCC1 axis.","authors":"Yanping Gui, Hongkun Qin, Xinyu Zhang, Qianqian Chen, Fangyu Ye, Geng Tian, Shihe Yang, Yuting Ye, Di Pan, Jieying Zhou, Xiangshan Fan, Yajing Wang, Li Zhao","doi":"10.1093/neuonc/noae237","DOIUrl":"https://doi.org/10.1093/neuonc/noae237","url":null,"abstract":"Background: Glioma is the most prevalent and lethal tumor of the central nervous system. Routine treatment with Temozolomide (TMZ) would unfortunately result in inevitable recurrence and therapy resistance, severely limiting therapeutic efficacy. Tumor associated astrocytes (TAAs) are key components of the tumor microenvironment and increasing evidence has demonstrated that aberrant expression of Connexin43 (Cx43) was closely associated with glioma progression and TMZ resistance. However, the specific role of Cx43 in mediating TMZ resistance through glioma and astrocyte interactions has not been fully explored.Methods: The expression and prognostic value of Cx43 were evaluated in tumor samples and clinical databases. ShRNA-medicated knockdown and Gfap-Cre Cx43flox/flox gene mouse were used to assessed the role and functional significance of Cx43 in vitro and in vivo. Moreover, we performed mass spectrometry analysis, chromatin immunoprecipitation, and other biochemical assays to define the molecular mechanisms by which Cx43 promotes TMZ resistance.Results: We confirmed that upregulation of Cx43 expression between TAAs and glioma cells contributed to TMZ resistance and tumor recurrence. Genetic knockdown or pharmacological inhibition of Cx43 enhanced TMZ-induced cytotoxicity. Mechanistically, elevated Cx43 expression induced β-catenin accumulation at the cell surface of glioma cells, suppressing TCF/LEF transcription, This led to impaired miR-205-5p expression and subsequent activation of E2F1/ERCC1 axis, which eventually led to chemoresistance.Conclusions: Our study reveals a novel regulatory mechanism in which the Cx43/miR-205-5p/E2F1/ERCC1 axis contributes to TMZ resistance in glioma. These findings further highlight the potential of targeting Cx43 as a therapeutic strategy in glioma.","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":""},"PeriodicalIF":16.4,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142605294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0